MDT
96.1
-0.44%↓
A
137.81
-0.48%↓
VEEV
224.76
+0.38%↑
HQY
92.67
-0.47%↓
PHR.US
16.99
-0.18%↓
MDT
96.1
-0.44%↓
A
137.81
-0.48%↓
VEEV
224.76
+0.38%↑
HQY
92.67
-0.47%↓
PHR.US
16.99
-0.18%↓
MDT
96.1
-0.44%↓
A
137.81
-0.48%↓
VEEV
224.76
+0.38%↑
HQY
92.67
-0.47%↓
PHR.US
16.99
-0.18%↓
MDT
96.1
-0.44%↓
A
137.81
-0.48%↓
VEEV
224.76
+0.38%↑
HQY
92.67
-0.47%↓
PHR.US
16.99
-0.18%↓
MDT
96.1
-0.44%↓
A
137.81
-0.48%↓
VEEV
224.76
+0.38%↑
HQY
92.67
-0.47%↓
PHR.US
16.99
-0.18%↓
24h
Aktuell
Min
Max
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +11.93% upside |
By Acuity
50%
50%
149 / 374 Ranking in Healthcare
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
24. Okt. 2025, 13:04 UTC
Eli Lilly Agrees to Acquire Adverum Biotechnologies
DJ
Lesen
9. Dez. 2025, 13:32 UTC
Eli Lilly: Parties Expect to Consummate the Acquisition on Dec 9 >LLY
DJ
Lesen
9. Dez. 2025, 13:32 UTC
Lilly and Purchaser Accepted for Payment, and Will Promptly Pay, for All Shrs
DJ
Lesen
9. Dez. 2025, 13:29 UTC
Lilly and Adverum Announce Expiration and Completion of Adverum Tender Offer and Acquisition
DJ
Lesen
24. Okt. 2025, 12:34 UTC
Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY
DJ
Lesen
24. Okt. 2025, 12:34 UTC
Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY
DJ
Lesen
24. Okt. 2025, 12:33 UTC
Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY
DJ
Lesen
24. Okt. 2025, 12:30 UTC
Lilly To Acquire Adverum Biotechnologies >LLY ADVM
DJ
Lesen
Kursveränderung
By TipRanks
12-Monats-Prognose
Durchschnitt 4.88 USD 11.93%
Hoch 5.5 USD
Tief 4 USD
Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Adverum Biotechnologies Inc – Dist angeboten haben.
By TipRanks
Buy
5 ratings
2
Buy
3
Halten
0
Sell
Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Adverum Biotechnologies Inc – Dist abgegeben haben.
By Acuity
Nachrichtenstimmung
Neutral
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Unterdurchschnittlich
$